Third Harmonic Bio Inc.

NASDAQ THRD

Data sourced from

and

Download Data

Third Harmonic Bio Inc. Total Liabilities to Total Assets Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2024: -93.56%

Third Harmonic Bio Inc. Total Liabilities to Total Assets Ratio 1 year YoY Change (%) is -93.56% for the Trailing 12 Months (TTM) ending March 31, 2024, a -32.90% change year over year. The total liabilities to total assets ratio measures the proportion of total liabilities to total assets. It is calculated by dividing the total liabilities by the total assets. This ratio provides insights into the company's financial leverage and the proportion of its assets financed by liabilities. A higher ratio indicates a higher level of financial risk and reliance on liabilities for asset acquisition. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Third Harmonic Bio Inc. Total Liabilities to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.40, a -70.40% change year over year.
Third Harmonic Bio Inc. Total Liabilities to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 1.36.

NASDAQ: THRD

Third Harmonic Bio Inc.

CEO	Ms. Natalie C. Holles
IPO Date	Sept. 14, 2022
Location	United States
Headquarters	300 Technology Square, Cambridge, MA, United States, 02139
Employees	31
Sector	Healthcare
Industry	Biotechnology

Description

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.

Key trends